The impact of the introduction of fidaxomicin on the management of Clostridium difficile
infection in 7 NHS secondary care Trusts in England.
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile
responsible for a nosocomial outbreak of Clostridium difficile
Molecular epidemiology and susceptibility profiles of Clostridium difficile
in New Zealand, 2009.
Samie A, Obi CL, Franasiak J, et al PCR detection of Clostridium difficile
triose phosphate isomerase (tpi), Toxin A (tcdA), Toxin B (tcdB), Binary Toxin (cdtA, cdtB), and tcdC genes in Vhembe District, South Africa.
Established and potential risk factors for Clostridium difficile
infection associated with levofloxacin treatment.
Toxin production by an emerging strain of Clostridium difficile
associated with outbreaks of severe disease in North-America and Europe.
National point prevalence of Clostridium difficile
in US health care facility inpatients.
who are now part of Cwm Taf NHS Trust, must be commended for recognising the seriousness of their situation in the spring of last year and for taking urgent steps to manage the Clostridium difficile
Nosocomial outbreaks caused by toxin A deficient (A- B+) Clostridium difficile
strains that resulted in the death of patients in Canada and US have been reported (15,16,17).
The primary objective of our study was to determine the baseline characteristics of in-patients with hospital acquired Clostridium difficile
and to ascertain their eventual outcomes, and thus evaluate the effectiveness of disease severity in predicting mortality, morbidity at discharge and discharge destination.
For example, although a patient may have Clostridium difficile
, the cause of death is often attributable to an entirely separate disease or episode.